{"preliminary_commentary":{"by_channel":{"x_thread":3,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["nivolumab","ipilimumab"]],"indication":"microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer","name":"NIPICOL","nct_id":"NCT03350126","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nipicol-nct03350126. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"NIPICOL","arms":[{"description":"Therapy induction (12 weeks) Nivolumab (IV) and Ipilimumab (IV) - every 21 days - 4 cycles Then Nivolumab (IV) alone every 15 days - 20 cycles - until 12 months","label":"Experimental arm","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2025-12","type":"ESTIMATED"},"conditions":["Metastatic Cancer Colorectal"],"enrollment":{"count":57,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Ipilimumab 200 MG in 40 ML Injection","otherNames":[],"type":"DRUG"},{"name":"Nivolumab 10 MG/ML","otherNames":[],"type":"DRUG"}],"last_update":"2025-07-23","lead_sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","official_title":"Interest of iRECIST Radiological Assessment for Disease Control Rate (DCR) for Evaluation of Patients With Metastatic Colorectal Cancer dMMR and/or MSI Treated With Nivolumab and Ipilimumab. A GERCOR Open-label Phase II Study NIPICOL C17-01","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2020-01-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Disease Control Rate (DCR)","timeFrame":"At 12 weeks"}],"references":[{"citation":"Depotte L, Nay P, Borg C, Meurisse A, Henriques J, Bennouna J, De La Fouchardiere C, Tougeron D, Mazard T, Chibaudel B, Tournigand C, Vernerey D, Pigneur F, Andre T, Cohen R. Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study. J Immunother Cancer. 2025 May 19;13(5):e011220. doi: 10.1136/jitc-2024-011220.","pmid":"40389373","type":"DERIVED"},{"citation":"Ratovomanana T, Nicolle R, Cohen R, Diehl A, Siret A, Letourneur Q, Buhard O, Perrier A, Guillerm E, Coulet F, Cervera P, Benusiglio P, Labreche K, Colle R, Collura A, Despras E, Le Rouzic P, Renaud F, Cros J, Alentorn A, Touat M, Ayadi M, Bourgoin P, Prunier C, Tournigand C, Fouchardiere C, Tougeron D, Jonchere V, Bennouna J, de Reynies A, Flejou JF, Svrcek M, Andre T, Duval A. Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability. Ann Oncol. 2023 Aug;34(8):703-713. doi: 10.1016/j.annonc.2023.05.010. Epub 2023 Jun 1.","pmid":"37269904","type":"DERIVED"},{"citation":"Ratovomanana T, Cohen R, Svrcek M, Renaud F, Cervera P, Siret A, Letourneur Q, Buhard O, Bourgoin P, Guillerm E, Dorard C, Nicolle R, Ayadi M, Touat M, Bielle F, Sanson M, Le Rouzic P, Buisine MP, Piessen G, Collura A, Flejou JF, de Reynies A, Coulet F, Ghiringhelli F, Andre T, Jonchere V, Duval A. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. Gastroenterology. 2021 Sep;161(3):814-826.e7. doi: 10.1053/j.gastro.2021.05.007. Epub 2021 May 13.","pmid":"33992635","type":"DERIVED"},{"citation":"Cohen R, Bennouna J, Meurisse A, Tournigand C, De La Fouchardiere C, Tougeron D, Borg C, Mazard T, Chibaudel B, Garcia-Larnicol ML, Svrcek M, Vernerey D, Menu Y, Andre T. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. J Immunother Cancer. 2020 Nov;8(2):e001499. doi: 10.1136/jitc-2020-001499.","pmid":"33148693","type":"DERIVED"}],"start_date":{"date":"2017-12-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab","url":"https://clinicaltrials.gov/study/NCT03350126"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nipicol-nct03350126"}